Trial · NCT02969915
Strategies to Improve the HIV Care Continuum Among Key Populations in India
NCT02969915, Not applicable, Completed, Johns Hopkins University; results first posted 2022-12-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Strategies to Improve the HIV Care Continuum Among Key Populations in India. Trials, record NCT02969915. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02969915
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Strategies to Improve the HIV Care Continuum Among Key Populations in India
- NCT number
- NCT02969915
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 2,314 participants, actual
- Lead sponsor
- Johns Hopkins University
- Conditions
- HIV Infections
- Interventions
- Incentives, Integrated Care Centers
- First posted
- 2016-11-21
- Last updated
- 2025-12-15
- Results first posted
- 2022-12-22
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Participants Surviving With Viral Suppression | 12 months | Viral Suppression defined as HIV RNA \<150 copies/mL |
| Secondary | Proportion of Participants Surviving With Viral Suppression | 6 months | Viral suppression defined as HIV RNA \<150 copies/mL |
| Secondary | Proportion of Participants Surviving With Viral Suppression | 18 months | Viral suppression defined as HIV RNA \<150 copies/mL |
| Secondary | Proportion of Participants Surviving With Viral Suppression | 24 months | Viral suppression defined as HIV RNA \<150 copies/mL |
| Secondary | Proportion of Participants With Viral Suppression at One or More Follow-up Visits | 24 months | Proportion with viral suppression (HIV RNA \<150 copies/mL) at one or more follow-up visits |
| Secondary | Antiretroviral Therapy (ART) Initiation | 12 months | Rate of ART initiation among those naive to ART at baseline. This is reported as the proportion of participants who initiated ART. |
| Secondary | Retention to HIV Care | 12 months | Proportion of participants who attended one or more visits to a government ART clinic in both the 0 to 6 month period and the 6 to 12 month period. |
| Secondary | ART Adherence | 12 months | Proportion of participants who had a medication possession ratio of 0.9 or higher after starting ART |
| Secondary | Mortality | 12 months | All-cause mortality |
Source ClinicalTrials.gov
Outcomes9
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Proportion of Participants Surviving With Viral Suppression | 12 months | proportion of participants | NUMBER | |
| SECONDARY | Proportion of Participants Surviving With Viral Suppression | 6 months | Proportion of participants | NUMBER | |
| SECONDARY | Proportion of Participants Surviving With Viral Suppression | 18 months | Overall number of participants analyzed is equal to enrolled cohort minus participants who were censored at the 18-month visit due to COVID-related stoppage. | Proportion of participants | NUMBER |
| SECONDARY | Proportion of Participants Surviving With Viral Suppression | 24 months | Overall number of participants analyzed is equal to enrolled cohort minus participants who were censored at the 24-month visit due to COVID-related stoppage. | Proportion of participants | NUMBER |
| SECONDARY | Proportion of Participants With Viral Suppression at One or More Follow-up Visits | 24 months | Proportion of participants | NUMBER | |
| SECONDARY | Antiretroviral Therapy (ART) Initiation | 12 months | This analysis includes only participants who had never started ART previously | Proportion of participants | NUMBER |
| SECONDARY | Retention to HIV Care | 12 months | Proportion of participants | NUMBER | |
| SECONDARY | ART Adherence | 12 months | proportion of participants | NUMBER | |
| SECONDARY | Mortality | 12 months | Proportion of participants | NUMBER |
Source ClinicalTrials.gov
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Participants Surviving With Viral Suppression | Incentives | 0.494 | proportion of participants | ||
| Proportion of Participants Surviving With Viral Suppression | Usual Care | 0.353 | proportion of participants | ||
| Proportion of Participants Surviving With Viral Suppression | Incentives | 0.509 | Proportion of participants | ||
| Proportion of Participants Surviving With Viral Suppression | Usual Care | 0.365 | Proportion of participants | ||
| Proportion of Participants Surviving With Viral Suppression | Incentives | 0.497 | Proportion of participants | ||
| Proportion of Participants Surviving With Viral Suppression | Usual Care | 0.358 | Proportion of participants | ||
| Proportion of Participants Surviving With Viral Suppression | Incentives | 0.471 | Proportion of participants | ||
| Proportion of Participants Surviving With Viral Suppression | Usual Care | 0.325 | Proportion of participants | ||
| Proportion of Participants With Viral Suppression at One or More Follow-up Visits | Incentives | 0.640 | Proportion of participants | ||
| Proportion of Participants With Viral Suppression at One or More Follow-up Visits | Usual Care | 0.498 | Proportion of participants |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 results by groupParticipant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Incentives | 1,114 | 8 |
| Overall Study | STARTED | Usual Care | 1,200 | 8 |
| Overall Study | 6-month Follow-up | Incentives | 901 | 8 |
| Overall Study | 6-month Follow-up | Usual Care | 968 | 8 |
| Overall Study | 12-month Follow-up | Incentives | 826 | 8 |
| Overall Study | 12-month Follow-up | Usual Care | 885 | 8 |
| Overall Study | 18-month Follow-up | Incentives | 778 | 8 |
| Overall Study | 18-month Follow-up | Usual Care | 824 | 8 |
| Overall Study | COMPLETED | Incentives | 421 | 8 |
| Overall Study | COMPLETED | Usual Care | 492 | 8 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Death | General disorders | Incentives | 104 | 1,114 | 104 |
| serious | Death | General disorders | Usual Care | 125 | 1,200 | 125 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Incentives | 104 | 1,114 |
| Total, all-cause mortality | Usual Care | 125 | 1,200 |
| Total, other adverse events | Incentives | 0 | 1,114 |
| Total, other adverse events | Usual Care | 0 | 1,200 |
| Total, serious adverse events | Incentives | 104 | 1,114 |
| Total, serious adverse events | Usual Care | 125 | 1,200 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants2
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| K24DA035684 | Treatment outcomes and comorbidity in HIV-infected IDU | LUCAS, GREGORY M | JOHNS HOPKINS UNIVERSITY | NATIONAL INSTITUTE ON DRUG ABUSE | 2014 to 2024 | NIH RePORTER |
| R01DA041034 | Strategies to improve the HIV care continuum among key populations in India | LUCAS, GREGORY M; MEHTA, SHRUTI H | JOHNS HOPKINS UNIVERSITY | NATIONAL INSTITUTE ON DRUG ABUSE | 2015 to 2021 | NIH RePORTER |
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Incentives vs Usual Care: deaths from any cause | Trial comparisons |
| Incentives vs Usual Care: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02969915
GET https://conductscience.org/api/trials/v1/NCT02969915/registered